321 related articles for article (PubMed ID: 1913640)
1. Pharmacokinetics of intravesical mitomycin C in superficial bladder cancer patients.
Dalton JT; Wientjes MG; Badalament RA; Drago JR; Au JL
Cancer Res; 1991 Oct; 51(19):5144-52. PubMed ID: 1913640
[TBL] [Abstract][Full Text] [Related]
2. Bladder wall penetration of intravesical mitomycin C in dogs.
Wientjes MG; Dalton JT; Badalament RA; Drago JR; Au JL
Cancer Res; 1991 Aug; 51(16):4347-54. PubMed ID: 1907883
[TBL] [Abstract][Full Text] [Related]
3. Penetration of mitomycin C in human bladder.
Wientjes MG; Badalament RA; Wang RC; Hassan F; Au JL
Cancer Res; 1993 Jul; 53(14):3314-20. PubMed ID: 8324743
[TBL] [Abstract][Full Text] [Related]
4. Bladder tissue uptake of mitomycin C during intravesical therapy is linear with drug concentration in urine.
Gao X; Au JL; Badalament RA; Wientjes MG
Clin Cancer Res; 1998 Jan; 4(1):139-43. PubMed ID: 9516962
[TBL] [Abstract][Full Text] [Related]
5. Intravesical electromotive mitomycin C versus passive transport mitomycin C for high risk superficial bladder cancer: a prospective randomized study.
Di Stasi SM; Giannantoni A; Stephen RL; Capelli G; Navarra P; Massoud R; Vespasiani G
J Urol; 2003 Sep; 170(3):777-82. PubMed ID: 12913696
[TBL] [Abstract][Full Text] [Related]
6. Bladder tissue pharmacokinetics and antitumor effect of intravesical 5-fluorouridine.
Song D; Wientjes MG; Gan Y; Au JL
Clin Cancer Res; 1997 Jun; 3(6):901-9. PubMed ID: 9815765
[TBL] [Abstract][Full Text] [Related]
7. Systemic absorption and pharmacokinetics of single-dose early intravesical mitomycin C after transurethral resection of non-muscle-invasive bladder cancer.
Maffezzini M; Campodonico F; Manuputty EE; Puntoni M; Martelli A; Marini V; Tamagno S; Mattioli F
Urology; 2013 Aug; 82(2):400-4. PubMed ID: 23791221
[TBL] [Abstract][Full Text] [Related]
8. Intravesical thermo-chemotherapy based on conductive heat: a first pharmacokinetic study with mitomycin C in superficial transitional cell carcinoma patients.
Milla P; Fiorito C; Soria F; Arpicco S; Cattel L; Gontero P
Cancer Chemother Pharmacol; 2014 Mar; 73(3):503-9. PubMed ID: 24442034
[TBL] [Abstract][Full Text] [Related]
9. Effect of local hyperthermia of the bladder on mitomycin C pharmacokinetics during intravesical chemotherapy for the treatment of superficial transitional cell carcinoma.
Paroni R; Salonia A; Lev A; Da Pozzo LF; Cighetti G; Montorsi F; Rigatti P; Colombo R
Br J Clin Pharmacol; 2001 Sep; 52(3):273-8. PubMed ID: 11560559
[TBL] [Abstract][Full Text] [Related]
10. Increasing medical staff safety by using a closed system for intravesical instillation of mitomycin C.
Haifler M; Lang E; Sabler I; Gutman Y; Lindner A; Zisman A
Urology; 2010 Sep; 76(3):649-51. PubMed ID: 20493518
[TBL] [Abstract][Full Text] [Related]
11. The effect of repeat transurethral resection on recurrence and progression rates in patients with T1 tumors of the bladder who received intravesical mitomycin: a prospective, randomized clinical trial.
Divrik RT; Yildirim U; Zorlu F; Ozen H
J Urol; 2006 May; 175(5):1641-4. PubMed ID: 16600720
[TBL] [Abstract][Full Text] [Related]
12. Increasing patient comfort by optimized postoperative administration of intravesical mitomycin C.
Stoehr B; Mueller T; Granig T; Zangerl F; Steiner H
BJU Int; 2008 Dec; 102(11):1556-9. PubMed ID: 18691179
[TBL] [Abstract][Full Text] [Related]
13. Use of pharmacologic data and computer simulations to design an efficacy trial of intravesical mitomycin C therapy for superficial bladder cancer.
Wientjes MG; Badalament RA; Au JL
Cancer Chemother Pharmacol; 1993; 32(4):255-62. PubMed ID: 8324866
[TBL] [Abstract][Full Text] [Related]
14. Penetration of intravesical doxorubicin in human bladders.
Wientjes MG; Badalament RA; Au JL
Cancer Chemother Pharmacol; 1996; 37(6):539-46. PubMed ID: 8612307
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of intra-arterial mitomycin C in the chemoembolization treatment of liver metastases with polyvinylalcohol or degradable starch microspheres.
Rump AF; Woschée U; Theisohn M; Fischbach R; Heindel W; Lackner K; Klaus W
Eur J Clin Pharmacol; 2002 Oct; 58(7):459-65. PubMed ID: 12389068
[TBL] [Abstract][Full Text] [Related]
16. Bladder tissue pharmacokinetics of intravesical mitomycin C and suramin in dogs.
Hu L; Wientjes MG; Li J; Au JL
AAPS J; 2010 Dec; 12(4):586-91. PubMed ID: 20625863
[TBL] [Abstract][Full Text] [Related]
17. Urinary pH is highly associated with tumor recurrence during intravesical mitomycin C therapy for nonmuscle invasive bladder tumor.
Maeda T; Kikuchi E; Matsumoto K; Miyajima A; Oya M
J Urol; 2011 Mar; 185(3):802-6. PubMed ID: 21239010
[TBL] [Abstract][Full Text] [Related]
18. Long-term efficacy of maintenance bacillus Calmette-Guérin versus maintenance mitomycin C instillation therapy in frequently recurrent TaT1 tumours without carcinoma in situ: a subgroup analysis of the prospective, randomised FinnBladder I study with a 20-year follow-up.
Järvinen R; Kaasinen E; Sankila A; Rintala E;
Eur Urol; 2009 Aug; 56(2):260-5. PubMed ID: 19395154
[TBL] [Abstract][Full Text] [Related]
19. Pharmacodynamics of mitomycin C in cultured human bladder tumors.
Schmittgen TD; Wientjes MG; Badalament RA; Au JL
Cancer Res; 1991 Aug; 51(15):3849-56. PubMed ID: 1906778
[TBL] [Abstract][Full Text] [Related]
20. Phase I clinical trial and pharmacokinetics of intravesical mitomycin C in dogs with localized transitional cell carcinoma of the urinary bladder.
Abbo AH; Jones DR; Masters AR; Stewart JC; Fourez L; Knapp DW
J Vet Intern Med; 2010; 24(5):1124-30. PubMed ID: 20695986
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
